Independent directory Public ClinicalTrials.gov records United States
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10499
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 241–252 of 10,499 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
Conditions
Nonsegmental Vitiligo
Interventions
Zasocitinib, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Bryant, Arkansas • Fountain Valley, California • Fremont, California + 16 more
Conditions
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
Interventions
Ubamatamab, Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 1Phase 2 Interventional

Opt-IVF for Personalized Medicine for Normal Responders

NCT07856082
Conditions
Ivf
Interventions
Opt-IVF, control
Device · Other
Lead sponsor
Urmila DIwekar
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more
Conditions
Arthritis, Psoriatic
Interventions
Icotrokinra, Placebo, Active reference comparator
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
Conditions
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions
Proton Therapy, Photon Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
27
States / cities
Atlanta, Georgia • Warrenville, Illinois • Baltimore, Maryland + 18 more
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
Conditions
Hearing Loss, Bilateral Sensorineural
Interventions
Commercially available Receiver in the Canal (RIC) hearing devices, Hearing Aids plus Remote Microphone System
Device
Lead sponsor
Sonova AG
Industry
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Aurora, Illinois
Conditions
Non Small Cell Lung Cancer, NSCLC
Interventions
Cemiplimab, Platinum-based chemotherapy, Marlotamig, REGN10597
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
12
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 8 more
Active, not recruiting Phase 2 Interventional

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948
Conditions
Atopic Dermatitis
Interventions
APG777, Placebo
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Tezepelumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more